Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Arialysarialysrx.comArialys Therapeutics develops precision medicines to block pathogenic autoantibodies that target the brain, focusing on autoimmune neuropsychiatric diseases. Its lead therapeutic, ART5803, is a clinical-stage antibody designed to treat anti-NMDA receptor encephalitis by rescuing NMDA receptor function.
Parse Score
